Study of ARDS subtypes for targeted treatment
Part of Lungs & breathing clinical trials.
This study looks at different types of inflammation in patients with Acute Respiratory Distress Syndrome (ARDS), a serious lung condition. It aims to find which treatments work best for each subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with ARDS using the latest definition.
- Your ARDS started within the last 72 hours.
- You are not expected to die within the next 24 hours.
- You are not currently on a machine that does the work of your heart and lungs (ECMO).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how placing patients on their stomach (prone positioning) affects those with serious lung failure (ARDS) who are on a breathing machine. It aims to learn more about the best practices for this treatment in the ICU.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study looks at a specific breathing event (“avalanche phenomenon”) when the lungs are opened in people with early, moderate-to-severe ARDS. The goal is to understand what’s happening in the lungs and whether it can guide better care.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
This study is testing whether certain proteins in the blood (sRAGE, CC16, and Syndecan-1) can help predict if patients with severe chest trauma will develop a serious lung condition called ARDS or have a higher risk of death. By measuring these proteins early, doctors might be able to identify high-risk patients sooner and provide more targeted care.
This study looks at different patterns in patients with a severe lung condition called ARDS, to better understand why some respond to treatments differently. You may help doctors learn how to personalize care.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.